ArticleACS omega2026
Antipyretic and Antinociceptive Activities of Tri-Phol-That Extract and Its Flavonoids:
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the common use of herbal medicines rich in flavonoids to treat fever and pain, the pharmacological mechanisms involved in these effects are poorly understood. Therefore, this study assessed the antipyretic and analgesic effects of Tri-Phol-That extract, characterized its major flavonoids, and investigated its possible molecular interactions with key inflammatory mediators. The antipyretic activity was evaluated against a turpentine-induced pyrexia model in mice. Analgesic activity was evaluated using the acetic acid-induced writhing, tail immersion, and hot plate tests. The concentration of rutin, quercetin, and kaempferol was determined by high-performance liquid chromatography. Molecular docking was performed using GNINA against COX-2 (mouse: 1CX2, human: 5KIR), COX-1 (ovine: 3N8X), and mPGES-1 (human: 4YL1). Interaction profile studies were also performed in the Discovery Studio 2021. The hydroethanolic extract lowered rectal temperature in a dose-dependent manner, with maximum inhibition occurring at 100-200 mg/kg, although the effect was less potent than that of tolfenamic acid. The acetic acid-induced writhing test also showed strong dose-dependent peripheral antinociceptive activity with 84.64% inhibition at 200 mg/kg of extract, comparable to tolfenamic acid. The central analgesic effects of extracts were observed in hot plate tests. Weak central analgesic effects were also observed in tail immersion tests. HPLC analysis indicated rutin (4.01 μg/g), kaempferol (2.13 μg/g), and quercetin (0.96 μg/g) were the most abundant flavonoid compounds. Based on docking results, quercetin had the strongest binding affinity toward COX-2 (-8.44 kcal/mol). Rutin also exhibited the strongest binding affinity toward COX-1 (-7.55 kcal/mol) among the flavonoids tested. On the other hand, kaempferol exhibited the strongest binding affinity toward mPGES-1 (-9.97 kcal/mol). Results also showed that rutin, quercetin, and kaempferol interacted with catalytic residues of ARG120, TYR355, TYR385, SER530, and SER127. Thus, it can be concluded that the extract of Tri-Phol-That had strong antipyretic and analgesic effects via multi-target inhibition of COX-1, COX-2, and mPGES-1, possibly due to the combined effects of rutin, quercetin, and kaempferol. These results support the traditional medicinal use of this extract and provide justification for further investigation as a phytotherapeutic agent.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.